Table 1.
Proportion of E. coli isolates non-susceptible to antimicrobials tested by age and sex, sentinel and routine data, 13 November 2017 to 12 February 2018
| Antibiotic | Sex | Age group, years | Sentinel data |
Routine data |
Difference in proportion non- susceptible (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|---|
| tested | non- susceptible | percentage (95% CI) | tested | non- susceptible | percentage (95% CI) | ||||
| Trimethoprim | |||||||||
| F | 18–44 | 55 | 15 | 27.3 (16.5–41.2) | 254 | 75 | 29.5 (24.1–35.6) | −2.2 (−16.4 to 11.9) | |
| 45–64 | 24 | 7 | 29.2 (13.4–51.3) | 108 | 44 | 40.7 (31.5–50.6) | −11.5 (−34.5 to 11.4) | ||
| ≥65 | 20 | 6 | 30.0 (12.8–54.3) | 121 | 41 | 33.9 (25.7–43.1) | −3.9 (−28.6 to 20.8) | ||
| M | 18–44 | 1 | 0 | 0.0 (0.0–94.5) | 16 | 5 | 31.3 (12.1–58.5) | −31.3 (−85.2 to 22.7) | |
| 45–64 | 6 | 0 | 0.0 (0.0–48.3) | 20 | 4 | 20.0 (6.6–44.3) | −20 (−48.4 to 8.4) | ||
| ≥65 | 4 | 3 | 75.0 (21.9–98.7) | 22 | 12 | 54.6 (32.7–75.0) | 20.4 (−41.6 to 82.5) | ||
| total | 110 | 31 | 28.2 (20.2–37.7) | 542a | 181 | 33.4 (29.5–37.6) | −5.2 (−15.1 to 4.6) | ||
| Nitrofurantoin | |||||||||
| F | 18–44 | 55 | 0 | 0.0 (0.0–8.1) | 254 | 3 | 1.2 (0.3–3.7) | −1.2 (−3.6 to 1.3) | |
| 45–64 | 24 | 0 | 0.0 (0.0–17.2) | 108 | 0 | 0.0 (0.0–4.3) | 0 | ||
| ≥65 | 20 | 1 | 5.0 (0.3–27.0) | 121 | 3 | 2.5 (0.6–7.6) | 2.5 (−9.9 to 15.0) | ||
| M | 18–44 | 1 | 0 | 0.0 (0.0–94.5) | 16 | 0 | 0.0 (0.0–24.1) | 0 | |
| 45–64 | 6 | 0 | 0.0 (0.0–48.3) | 20 | 1 | 5.0 (0.3–27.0) | −5.0 (−19.6 to 9.6) | ||
| ≥65 | 4 | 0 | 0.0 (0.0–60.4) | 22 | 1 | 4.6 (0.24–24.9) | −4.6 (−17.8 to 8.7) | ||
| total | 110 | 1 | 0.9 (0.0–5.7) | 542a | 8 | 1.5 (0.7–3.0) | −0.6 (−3.2 to 2.0) | ||
| Amoxicillin/ clavulanic acid | |||||||||
| F | 18–44 | 55 | 19 | 34.6 (22.6–48.7) | 254 | 104 | 40.9 (34.9–47.3) | −6.3 (−21.5 to 8.7) | |
| 45–64 | 24 | 7 | 29.2 (13.4–51.3) | 108 | 50 | 46.3 (36.7–56.1) | −17.1 (−40.1 to 5.9) | ||
| ≥65 | 20 | 9 | 45.0 (23.8–68.0) | 121 | 55 | 45.5 (36.5–54.7) | −0.5 (−24.4 to 23.5) | ||
| M | 18–44 | 1 | 1 | 100.0 (5.5–100.0) | 16 | 5 | 31.3 (12.1–58.5) | 68.7 (−7.1 to 100) | |
| 45–64 | 6 | 3 | 50.0 (18.8–81.2) | 20 | 10 | 50.0 (29.9–70.1) | 0 (−45.6 to 45.6) | ||
| ≥65 | 4 | 3 | 75.0 (21.9–98.7) | 22 | 16 | 72.7 (49.6–88.4) | 2.3 (−46.3 to 50.1) | ||
| total | 110 | 42 | 38.2 (29.2–48.0) | 542a | 241a | 44.5 (40.2–48.8) | −6.3 (−16.8 to 4.3) | ||
| Ciprofloxacin | |||||||||
| F | 18–44 | 55 | 7 | 12.7 (5.7–25.1) | 254 | 28 | 11.0 (7.57–15.69) | 1.7 (−9.0 to 12.4) | |
| 45–64 | 24 | 4 | 16.7 (5.5–38.2) | 108 | 20 | 18.5 (11.94–27.39) | −1.82 (−20.3 to 16.6) | ||
| ≥65 | 20 | 2 | 10.0 (1.8–33.1) | 121 | 23 | 19.0 (12.67–27.37) | −9.0 (−26.8 to 8.8) | ||
| M | 18–44 | 1 | 0 | 0.0 (0.0–94.5) | 16 | 3 | 18.8 (5.0–46.3) | −18.8 (−56.6 to 19.1) | |
| 45–64 | 6 | 0 | 0.0 (0.0–48.3) | 20 | 4 | 20 (6.6–44.3) | −20 (−48.4 to 8.4) | ||
| ≥65 | 4 | 1 | 25.0 (1.3–78.1) | 22 | 8 | 36.4 (18.0–59.2) | −11.4 (−69.7 to 47.0) | ||
| total | 110 | 14 | 12.7 (7.4–20.1) | 542a | 86 | 15.9 (12.9–19.3) | −3.2 (−10.6 to 4.4) | ||
| Cefalexin | |||||||||
| F | 18–44 | 55 | 4 | 7.3 (2.4–18.4) | 254 | 19 | 7.5 (4.7–11.6) | −0.2 (−8.0 to 7.6) | |
| 45–64 | 24 | 1 | 4.2 (0.2–23.1) | 108 | 13 | 12.0 (6.8–20.1) | −7.8 (−20.5 to 4.8) | ||
| ≥65 | 20 | 2 | 10 (1.8–33.1) | 121 | 20 | 16.5 (10.6–24.6) | −6.5 (−24.1 to 11.1) | ||
| M | 18–44 | 1 | 0 | 0 (0.0–94.5) | 16 | 2 | 12.5 (2.2–39.6) | −12.5 (−41.2 to 16.2) | |
| 45–64 | 6 | 1 | 16.7 (0.9–63.5) | 20 | 3 | 15.0 (4.0–38.9) | 1.7 (−33.7 to 37.0) | ||
| ≥65 | 4 | 0 | 0 (0.0–60.4) | 22 | 7 | 31.8 (14.7–54.9) | −31.8 (−66.1 to 2.4) | ||
| total | 110 | 8 | 7.3 (3.4–14.3) | 542a | 65 | 12.0 (9.4–15.1) | −4.7 (−10.8 to 1.4) | ||
F, female; M, male.
a
Sex or age group unknown for some patients therefore age–sex denominators may not sum to total.